Literature DB >> 9661018

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

M A Pfaller1, R N Jones, G V Doern, K Kugler.   

Abstract

The SENTRY Program was established in January 1997 to measure the predominant pathogens and antimicrobial resistance patterns of nosocomial and community-acquired infections over a broad network of sentinel hospitals in the United States (30 sites), Canada (8 sites), South America (10 sites), and Europe (24 sites). During the first 6-month study period (January to June 1997), a total of 5,058 bloodstream infections (BSI) were reported by North American SENTRY participants (4,119 from the United States and 939 from Canada). In both the United States and Canada, Staphylococcus aureus and Escherichia coli were the most common BSI isolates, followed by coagulase-negative staphylococci and enterococci. Klebsiella spp., Enterobacter spp., Pseudomonas aeruginosa, Streptococcus pneumoniae, and beta-hemolytic streptococci were also among the 10 most frequently reported species in both the United States and Canada. Although the rank orders of pathogens in the United States and Canada were similar, distinct differences were noted in the antimicrobial susceptibilities of several pathogens. Overall, U.S. isolates were considerably more resistant than those from Canada. The differences in the proportions of oxacillin-resistant S. aureus isolates (26.2 versus 2.7% for U.S. and Canadian isolates, respectively), vancomycin-resistant enterococcal isolates (17.7 versus 0% for U.S. and Canadian isolates, respectively), and ceftazidime-resistant Enterobacter sp. isolates (30.6 versus 6.2% for U.S. and Canadian isolates, respectively) dramatically emphasize the relative lack of specific antimicrobial resistance genes (mecA, vanA, and vanB) in the Canadian microbial population. Among U.S. isolates, resistance to oxacillin among staphylococci, to vancomycin among enterococci, to penicillin among pneumococci, and to ceftazidime among Enterobacter spp. was observed in both nosocomial and community-acquired pathogens, although in almost every instance the proportion of resistant strains was higher among nosocomial isolates. Antimicrobial resistance continues to increase, and ongoing surveillance of microbial pathogens and resistance profiles is essential on national and international scales.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661018      PMCID: PMC105680     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  A statewide surveillance system for antimicrobial-resistant bacteria: New Jersey.

Authors:  S M Paul; L Finelli; G L Crane; K C Spitalny
Journal:  Infect Control Hosp Epidemiol       Date:  1995-07       Impact factor: 3.254

2.  Antibiotic-resistant bugs: when, where, and why?

Authors:  M T Osterholm; K L MacDonald
Journal:  Infect Control Hosp Epidemiol       Date:  1995-07       Impact factor: 3.254

3.  Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.

Authors:  S A Marshall; W W Wilke; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1998-03       Impact factor: 2.803

Review 4.  An overview of nosocomial infections, including the role of the microbiology laboratory.

Authors:  T G Emori; R P Gaynes
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

5.  New group tracks hospitals' drug-resistant bugs.

Authors:  R Voelker
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

6.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

7.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

8.  Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

Authors:  R N Jones; E N Kehrberg; M E Erwin; S C Anderson
Journal:  Diagn Microbiol Infect Dis       Date:  1994-08       Impact factor: 2.803

9.  National nosocomial infections surveillance system (NNIS): description of surveillance methods.

Authors:  T G Emori; D H Culver; T C Horan; W R Jarvis; J W White; D R Olson; S Banerjee; J R Edwards; W J Martone; R P Gaynes
Journal:  Am J Infect Control       Date:  1991-02       Impact factor: 2.918

10.  Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group.

Authors:  C H Ballow; J J Schentag
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

View more
  78 in total

1.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Impact of Antibiotic Resistance on the Treatment of Gram-negative Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  K A Gordon; J Fusco; D J Biedenbach; M A Pfaller; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.

Authors:  J A Karlowsky; L Nealy; D F Sahm; C Thornsberry; M E Jones
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

5.  Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Authors:  Andrea S Gershon; Joyce C S de Azavedo; Allison McGeer; Krystyna I Ostrowska; Deirdre Church; Daryl J Hoban; Godfrey K M Harding; Karl Weiss; Lewis Abbott; Fiona Smaill; Marie Gourdeau; Gilles Murray; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 6.  Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium.

Authors:  Armine M Sefton
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci.

Authors:  Junius Clark; Joan C Fung-Tomc; Beatrice Minassian; Yuan-Hwang Tsai; Hyekyung Yang; Elizabeth Huczko; Benjamin Kolek; Susan Chaniewski; Cheryl Ferraro; Rebecca Drain; Elizabeth Gradelski; Daniel P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 8.  Rhinosinusitis: Establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  Otolaryngol Head Neck Surg       Date:  2004-12       Impact factor: 3.497

9.  Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.

Authors:  Shawn R Lockhart; Murray A Abramson; Susan E Beekmann; Gale Gallagher; Stefan Riedel; Daniel J Diekema; John P Quinn; Gary V Doern
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

Review 10.  Rhinosinusitis: establishing definitions for clinical research and patient care.

Authors:  Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich
Journal:  J Allergy Clin Immunol       Date:  2004-12       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.